Overview

Safety, PK and Efficacy of CT-707 in Combination With Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

Status:
Recruiting
Trial end date:
2024-08-11
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmacokinetics and antineoplastic activity of CT-707 in combination with toripalimab and gemcitabine in patients with advanced pancreatic cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shouyao Holdings (Beijing) Co. LTD
Treatments:
Gemcitabine